Vladimir Hanes

507 total citations
40 papers, 385 citations indexed

About

Vladimir Hanes is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Vladimir Hanes has authored 40 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 26 papers in Oncology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Vladimir Hanes's work include Biosimilars and Bioanalytical Methods (28 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and HER2/EGFR in Cancer Research (15 papers). Vladimir Hanes is often cited by papers focused on Biosimilars and Bioanalytical Methods (28 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and HER2/EGFR in Cancer Research (15 papers). Vladimir Hanes collaborates with scholars based in United States, Germany and United Kingdom. Vladimir Hanes's co-authors include Vincent Chow, Richárd Márkus, Zhiying Pan, Patrícia Xavier Santi, Hans‐Christian Kolberg, Marco Colleoni, Gϋnter von Minckwitz, Jerome H. Goldschmidt, Serafín Morales and Z. Tomasevic and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Vladimir Hanes

39 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vladimir Hanes United States	11	319	248	159	59	41	40	385
Camille Vleminckx Netherlands	6	356 1.1×	123 0.5×	86 0.5×	120 2.0×	161 3.9×	7	430
Gerd R. Burmester Germany	3	148 0.5×	22 0.1×	55 0.3×	35 0.6×	54 1.3×	4	301
Karl Verpoort Germany	7	123 0.4×	222 0.9×	14 0.1×	38 0.6×	31 0.8×	10	370
Juan Ignacio Vargas United States	4	159 0.5×	109 0.4×	36 0.2×	19 0.3×	18 0.4×	11	547
Marie-Anne Damiette Smit United States	7	44 0.1×	261 1.1×	64 0.4×	7 0.1×	45 1.1×	11	402
Nathalie Varoqueaux France	7	52 0.2×	140 0.6×	32 0.2×	3 0.1×	29 0.7×	19	287
Д. В. Комов Russia	7	106 0.3×	158 0.6×	81 0.5×	18 0.3×	23 0.6×	21	248
Lisa Musick United States	9	55 0.2×	202 0.8×	41 0.3×	30 0.5×	4 0.1×	27	360
Eduardo J. Pennella United States	11	89 0.3×	416 1.7×	60 0.4×	14 0.2×	17 0.4×	33	578
Nikolay Delev United States	9	244 0.8×	71 0.3×	65 0.4×	4 0.1×	7 0.2×	24	409

Countries citing papers authored by Vladimir Hanes

Since Specialization

Citations

This map shows the geographic impact of Vladimir Hanes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Hanes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Hanes more than expected).

Fields of papers citing papers by Vladimir Hanes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Hanes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Hanes. The network helps show where Vladimir Hanes may publish in the future.

Co-authorship network of co-authors of Vladimir Hanes

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Hanes. A scholar is included among the top collaborators of Vladimir Hanes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Hanes. Vladimir Hanes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Judy S., David Sommerhalder, Manish Sharma, et al.. (2024). Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.. Journal of Clinical Oncology. 42(16_suppl). 2582–2582. 2 indexed citations

Blum, Lisa K., Anushka De Costa, Geoffrey W. Stone, et al.. (2024). Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors. Cancer Research. 84(6_Supplement). 3641–3641.

Kulasekararaj, Austin, Francesco Lanza, Saskia Langemeijer, et al.. (2024). Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology. 99(11). 2108–2117. 4 indexed citations

Kolberg, Hans‐Christian, et al.. (2021). Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. The Breast. 57. 95–103. 7 indexed citations

Kolberg, Hans‐Christian, Georgia Demetriou, & Vladimir Hanes. (2021). Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations. Oncology and Therapy. 9(1). 225–238. 1 indexed citations

Niederwieser, Dietger, Caroline Hamm, Patrick Cobb, et al.. (2020). Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. Targeted Oncology. 15(5). 599–611. 14 indexed citations

Goldschmidt, Jerome H. & Vladimir Hanes. (2020). The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab. Oncology and Therapy. 9(1). 213–223. 3 indexed citations

Niederwieser, Dietger, Caroline Hamm, Patrick Cobb, et al.. (2020). Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.. Journal of Clinical Oncology. 38(15_suppl). 8044–8044. 1 indexed citations

Chow, Vincent, et al.. (2020). A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris^®) in healthy male subjects. European Journal Of Haematology. 105(1). 66–74. 21 indexed citations

10.

Colleoni, Marco, Georgia Demetriou, Patrícia Xavier Santi, et al.. (2020). Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Drug Safety. 43(3). 233–242. 11 indexed citations

11.

Thatcher, Nicholas, Jerome H. Goldschmidt, Michael Thomas, et al.. (2019). Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clinical Cancer Research. 25(7). 2088–2095. 43 indexed citations

12.

Kolberg, Hans‐Christian, Marco Colleoni, Patrícia Xavier Santi, et al.. (2019). Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology. 14(6). 647–656. 12 indexed citations

13.

Thomas, Michael, Nick Thatcher, Jerome H. Goldschmidt, et al.. (2019). Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.. Journal of Clinical Oncology. 37(15_suppl). e20708–e20708. 1 indexed citations

14.

Minckwitz, Gϋnter von, Marco Colleoni, Hans‐Christian Kolberg, et al.. (2018). Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 19(7). 987–998. 84 indexed citations

15.

Hanes, Vladimir, Vincent Chow, Zhiying Pan, & Richárd Márkus. (2018). A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemotherapy and Pharmacology. 82(5). 899–905. 16 indexed citations

16.

Minckwitz, Gϋnter von, et al.. (2017). Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer. Annals of Oncology. 28. v44–v44. 8 indexed citations

17.

Márkus, Richárd, Vincent Chow, Zhiying Pan, & Vladimir Hanes. (2017). A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemotherapy and Pharmacology. 80(4). 755–763. 36 indexed citations

18.

Hanes, Vladimir, Vincent Chow, Nan Zhang, & Richárd Márkus. (2017). A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemotherapy and Pharmacology. 79(5). 881–888. 32 indexed citations

19.

Thatcher, Nick, Michael B. Thomas, Zhiying Pan, et al.. (2017). Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: Pharmacokinetic results and justification for extrapolation across bevacizumab indications.. Journal of Clinical Oncology. 35(15_suppl). 9050–9050. 2 indexed citations

20.

Hanes, Vladimir, et al.. (2016). Pharmacokinetic similarity of ABP 980 relative to trastuzumab in the Japanese subset: Results from a randomized, single-blind, single-dose, parallel group study in healthy subjects. 1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact